SEP 4, 2026 · PHASE 1/2 TRIAL
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 1b/2 study with no results posted; it documents the study design and planned outcomes only.
Reported
Estimated enrollment152
Study phasePhase 1b/2
Primary outcome (Part 1): DLTs, s…21 months after enrollment start